Dorothy “Dottie” Thomas, wife and research partner to 1990 Nobel laureate E. Donnall Thomas, died Jan. 9, at her home near Seattle. She was 92.
SETON HALL UNIVERSITY and Hackensack University Health Network announced plans to form a new, four-year school of medicine. The partnership will establish the only private school of medicine in New Jersey.
The Federation of American Societies for Experimental Biology called for a re-examination of the way research is funded in the U.S., in a report detailing the challenges facing researchers and the threats to continued progress in the field.
NAIYER RIZVI was named director of thoracic oncology and immunotherapeutics in medical oncology at NewYork-Presbyterian/Columbia University Medical Center. Rizvi comes from Memorial Sloan Kettering Cancer Center, where he was an attending physician and focused on thoracic immunotherapy.
JULIE BRAHMER was named director of the Thoracic Oncology Program at the Johns Hopkins Kimmel Cancer Center.
AVEO Oncology announced plans to cut its workforce by two-thirds, end its internal research functions, and vacate up to 80 percent of its facilities, including laboratory and vivarium locations. The biotechnology company was co-founded by Ronald DePinho, president of MD Anderson Cancer Center.
The stochastic process of stem cell divisions should not be equated with bad luck, said Barnett Kramer, director of the NCI Division of Cancer Prevention, focusing on misinterpretations of the “Bad Luck” paper by Cristian Tomasetti and Bert Vogelstein, of Johns Hopkins University School of Medicine.
How much of the potential to develop cancer is due to plain “bad luck”?
In May 2008, the Blue Devils of genomic medicine were facing a mortal threat.
MD Anderson, Intrexon, and Ziopharm announce sublicensing agreement with the University of Minnesota
MD ANDERSON CANCER CENTER, Intrexon Corporation and Ziopharm Oncology announced a sublicensing agreement for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.
